52,390 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 52,390 shares of the biopharmaceutical company's stock, valued at approximately $1,225,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. NBC Securities Inc. grew its position in TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 485 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in TG Therapeutics in the 2nd quarter valued at about $35,000. Blue Trust Inc. lifted its position in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 849 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics during the third quarter valued at about $53,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of TG Therapeutics in the 1st quarter valued at approximately $58,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Stock Up 1.5 %

TGTX traded up $0.52 on Friday, reaching $35.07. The company's stock had a trading volume of 2,577,314 shares, compared to its average volume of 4,453,207. The company has a market capitalization of $5.46 billion, a price-to-earnings ratio of -350.66 and a beta of 2.19. TG Therapeutics, Inc. has a fifty-two week low of $12.30 and a fifty-two week high of $36.50. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a 50 day moving average of $25.62 and a two-hundred day moving average of $21.70.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to analysts' expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business's revenue for the quarter was down 49.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.73 EPS. As a group, analysts forecast that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now owns 100,195 shares of the company's stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TGTX. B. Riley raised their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. TD Cowen started coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price for the company. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Finally, HC Wainwright raised their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $37.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.